Pain 2024 Jan 1;165(1):192-201. doi: 10.1097/j.pain.0000000000003012. Epub 2023 Aug 11. Aude Charron, Lucie Pepino, Pascale Malapert, Vincent Debrauwer, Francis Castets, Chiara Salio, Aziz Moqrich Abstract Decreased GABA levels in injury-induced loss of spinal inhibition are still under intense interest and debate. Here, we show that GAD67 haplodeficient
Modulation of the spinal N13 SEP component by high- and low-frequency electrical stimulation. Experimental pain models matter
Clinical neurophysiology 2023 Dec:156:28-37. doi: 10.1016/j.clinph.2023.08.022. Epub 2023 Oct 6. C Leone, G Di Pietro, Y Salman, E Galosi, G Di Stefano, O Caspani , L Garcia-Larrea, A Mouraux, R-D Treede, A Truini Abstract Objective: The N13 component of somatosensory evoked potential (N13 SEP) represents the segmental response of cervical dorsal
Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases
Headache Case Reports 2024 Jan;64(1):117-118.doi: 10.1111/head.14662. Epub 2023 Dec 29. Marion Beltramone, Sylvain Redon, Anne Donnet PMID: 38156514 DOI: 10.1111/head.14662
Application accuracy of Neuromate robot-guided deep brain stimulation procedures using the non-invasive frameless Neurolocate registration system
The International Journal of Medical Robotics and Computer Assisted Surgery 2023 Dec 13:e2610. doi: 10.1002/rcs.2610. Online ahead of print. Denys Fontaine , Fabien Almairac, Bruno Chiapello, Aurélie Leplus Abstract Objective: to measure the in vivo application accuracy of Neuromate robot-assisted
Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention
The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not
One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
The Journal of Headache and Pain 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4. M Lanteri-Minet, R Fabre, C Martin, K Pradat, A Alchaar, E Bozzolo, M L Duchene, E K Van Obberghen, A Donnet, D Fontaine Abstract Background: Randomized clinical trials have
Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study
The Journal of Headache and Pain 2023 Nov 8;24(1):151. doi: 10.1186/s10194-023-01683-1. Richard B Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L Reed, Kristina M Fanning, Dawn C Buse Abstract Background: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed
Why Europe needs a pain research strategy
European journal of pain Editorial – 2023 Nov;27(10):1147-1149. doi: 10.1002/ejp.2179. Epub 2023 Sep 4. Gisèle Pickering2, Mary O’Keeffe, Kirsty Bannister, Susanne Becker, Sonia Cottom, Felicia J Cox, Elon Eisenberg, David P Finn, Thomas Graven-Nielsen, Mira Meeus, Andre Mouraux, Thomas Tölle , Luis Garcia-Larrea, Brona M Fullen No abstract available PMID: 37664971 DOI: 10.1002/ejp.2179
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease
Neurology(R) Neuroimmunology & Neuroinflammation 2023 Aug 22;10(6):e200153.doi: 10.1212/NXI.0000000000200153. Print 2023 Nov. Florent Cluse , Marc Hermier, Genevieve Demarquay, Veronique Rogemond, Martial Mallaret, Juliette Svahn, Antoine Pegat, Jerome Honnorat, Emilien Bernard Abstract Objectives: Anti-IgLON5 disease (IgLON5-D) may present with a bulbar-onset motor neuron disease-like phenotype, mimicking bulbar-onset amyotrophic lateral
Beyond trial-and-error: Individualizing therapeutic transcranial neuromodulation for chronic pain
European Journal of Pain 2023 Oct;27(9):1065-1083. doi: 10.1002/ejp.2164. Epub 2023 Aug 19. Daniel Ciampi de Andrade, Luís García-Larrea Abstract Background and objective: Repetitive transcranial magnetic stimulation (rTMS) applied to the motor cortex provides supplementary relief for some individuals with chronic pain who are